adria_alegre_amoradria_alegre_amor

Adrián Alegre Amor

JEFE/A DE SERVICIO
Hematología y Hemoterapiaes/especialidades/hematologia-hemoterapia
Pedir cita
Ver más especialistas en Madridmadrid

es/cuadro-medico/hematologo

Datos destacados

  • Última publicación:
    A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies.

Datos del profesional

Hospital Universitario Quirónsalud Madrid
JEFE/A DE SERVICIO
Enero 2023 - Actualidad
Estudio
Hematología y Hemoterapia
hospital, Hospital Clínico Universitario de Salamanca
Medicina
Universidad Autónoma de Madrid
A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies.
Clinical Trial, Phase II, Clinical Trial, Phase I, Journal Article, Research Support, Non-U.S. Govt
A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma.
Journal Article, Research Support, Non-U.S. Govt
Agreements and uncertainties in autologous haematopoietic stem cell mobilization and collection. A Spanish consensus document.
Journal Article
Daratumumab Monotherapy for Relapsed or Refractory Multiple Myeloma: Results of an Early Access Treatment Protocol in Europe and Russia.
Journal Article
Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis.
Journal Article
Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis.
Journal Article, Comment
Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma.
Journal Article
Patient-reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON study.
Journal Article
Subgroup analysis of ICARIA-MM study in relapsed/refractory multiple myeloma patients with high-risk cytogenetics.
Journal Article
Pide cita con este profesional
Pedir cita